Cost-Effectiveness of Sarilumab Versus Adalimumab for Treating Patients with Active Rheumatoid Arthritis- A Markov Model Assessment
Abstract
Authors
Y Zhang I Freeman Y Yang
Y Zhang I Freeman Y Yang
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now